This company listing is no longer active
Radius Health Performance dei guadagni passati
Il passato criteri di controllo 0/6
Informazioni chiave
28.6%
Tasso di crescita degli utili
30.1%
Tasso di crescita dell'EPS
| Biotechs Crescita del settore | 17.0% |
| Tasso di crescita dei ricavi | 35.3% |
| Rendimento del capitale proprio | n/a |
| Margine netto | -30.7% |
| Ultimo aggiornamento sui guadagni | 30 Jun 2022 |
Aggiornamenti sulle prestazioni recenti
Recent updates
Radius Recycling Stays In The Scrap Pile
Jul 16Radius Recycling: An Attractive, But Volatile, Play On A Cleaner Future
Jun 03Radius stock rises as elacestrant gets FDA priority review to treat breast cancer subtype
Aug 11Reevaluating Radius Health
Feb 24Radius Health EPS misses by $0.02, misses on revenue
May 07When Will Radius Health, Inc. (NASDAQ:RDUS) Become Profitable?
Feb 23
Revisiting Radius Health
Feb 01Radius Health acquires global rights to RAD011 in Prader-Willi syndrome
Jan 06How Much Did Radius Health's(NASDAQ:RDUS) Shareholders Earn From Share Price Movements Over The Last Five Years?
Jan 01
Radius Health on-track for record quarterly revenue for TYMLOS-SC
Dec 15Ripartizione dei ricavi e delle spese
Come Radius Health guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.
Storia dei guadagni e delle entrate
| Data | Ricavi | Guadagni | Spese G+A | Spese di R&S |
|---|---|---|---|---|
| 30 Jun 22 | 223 | -69 | 129 | 121 |
| 31 Mar 22 | 217 | -73 | 127 | 122 |
| 31 Dec 21 | 230 | -70 | 130 | 131 |
| 30 Sep 21 | 228 | -76 | 138 | 128 |
| 30 Jun 21 | 249 | -60 | 134 | 134 |
| 31 Mar 21 | 247 | -87 | 140 | 151 |
| 31 Dec 20 | 239 | -109 | 143 | 159 |
| 30 Sep 20 | 232 | -113 | 144 | 158 |
| 30 Jun 20 | 200 | -136 | 148 | 149 |
| 31 Mar 20 | 191 | -128 | 150 | 131 |
| 31 Dec 19 | 173 | -133 | 155 | 115 |
| 30 Sep 19 | 152 | -149 | 163 | 104 |
| 30 Jun 19 | 133 | -169 | 170 | 100 |
| 31 Mar 19 | 115 | -203 | 179 | 99 |
| 31 Dec 18 | 99 | -221 | 186 | 98 |
| 30 Sep 18 | 72 | -251 | 193 | 97 |
| 30 Jun 18 | 58 | -259 | 197 | 91 |
| 31 Mar 18 | 37 | -259 | 199 | 84 |
| 31 Dec 17 | 22 | -254 | 189 | 81 |
| 30 Sep 17 | 14 | -236 | 167 | 82 |
| 30 Jun 17 | 1 | -224 | 138 | 89 |
| 31 Mar 17 | 0 | -199 | 104 | 97 |
| 31 Dec 16 | 0 | -183 | 80 | 105 |
| 30 Sep 16 | 0 | -163 | 62 | 104 |
| 30 Jun 16 | 0 | -145 | 51 | 95 |
| 31 Mar 16 | 0 | -125 | 40 | 84 |
| 31 Dec 15 | 0 | -102 | 31 | 68 |
Guadagni di qualità: RDUS is currently unprofitable.
Margine di profitto in crescita: RDUS is currently unprofitable.
Flusso di cassa libero e analisi degli utili
Analisi della crescita degli utili nel passato
Andamento degli utili: RDUS is unprofitable, but has reduced losses over the past 5 years at a rate of 28.6% per year.
Accelerare la crescita: Unable to compare RDUS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Guadagni vs Settore: RDUS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (24.5%).
Rendimento del capitale proprio
ROE elevato: RDUS's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.